Nanobiotix SA is a late-stage biotechnology company, which engages in the development of therapeutic approaches to the treatment of cancer. The company is headquartered in Paris, Ile-De-France and currently employs 103 full-time employees. The company went IPO on 2012-10-29. The firm designs and manufactures nanoparticles that safely enhance the efficacy of radiation therapy in the treatment of cancer. The company develops new tools for cancer that utilize a physical mode of action at the cellular level of the cancer cell. The firm's NanoXray technology comprises three products. Local treatment (surgery and radiotherapy) provides potential cure and gives the systemic treatment a better chance to life expectancy. NanoXray products are developed for the efficacy of radiotherapy in the tumor cell. Nanobiotix is a spin-off of the State University of New York (SUNY) at Buffalo.
How did NBTX's recent EPS compare to expectations?
The most recent EPS for Nanobiotix SA is $-0.39, not beating expectations of $0.55.
How did Nanobiotix SA NBTX's revenue perform in the last quarter?
Nanobiotix SA revenue for the last quarter is $-0.39
What is the revenue estimate for Nanobiotix SA?
According to 3 of Wall street analyst, the revenue estimate of Nanobiotix SA range from $24.57M to $22.93M
What's the earning quality score for Nanobiotix SA?
Nanobiotix SA has a earning quality score of /. The score is based on a four dimension of Profitability, Growth, Cash generation & Capital Allocation, and Leverage.
When does Nanobiotix SA report earnings?
Nanobiotix SA next earnings report is expected in 2026-06-29
What are Nanobiotix SA's expected earnings?
Nanobiotix SA expected earnings is $59.82M, according to wall-street analysts.
Did Nanobiotix SA beat earnings expectations?
Nanobiotix SA recent earnings of $5.95M does not beat expectations.